Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam Besylate vs Propofol for Deep Sedation in Critically Ill Patients
NCT05539521Phase 2Unknown
- Start
- Sep 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of remimazolam (2 arms). Primary endpoint: Percentage of time in the target sedation range without rescue sedation at 48 hours. Status: unknown.
02
Drugs
remimazolam
Beyond the preview
Go deeper on NCT05539521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05539521.